📋 Tender Overview
Contract awarded for Concentrate of recombinant factor viii minimum second generation along with delivery to regional blood donation and transfusion centers; procedure sign: zzp.zp.411.158.2026 parts: 1÷2 { "detected_language": "polish", "translated_text": "lot-0001, title: part 1. concentrate of recombinant factor viii minimum ii generation along with delivery to regional blood donation and hemotherapy centers., description: 1. the subject of the order is the delivery of a concentrate of recombinant factor viii minimum ii generation to ensure the continuity of treatment for patients with hemophilia a - hereinafter referred to as \"coagulation factor\", with availability category rp or rpz, to the entities indicated by the national blood center (hereinafter nck) or another authorized entity of direct recipients - regional blood donation and hemotherapy centers (hereinafter rckik), under the terms specified in the content of the swz. 2. total quantity (purchase size): 5,000,000 iu. 3. dose proportions in each delivery - according to swz. 4. the coagulation factor concentrate must be delivered with a set enabling its administration. 5. when selecting the most advantageous offer, the ordering party reserves the right to reduce the purchase of the medicinal product, but not more than 20% of each part of the aforementioned subject of the order, in the event of exceeding the amount allocated for the execution of the order or the emergence of objective and justified needs, especially changes in demand among patients. 6. the purchase is carried out under the health policy program of the minister responsible for health entitled \"national program for the treatment of patients with hemophilia and related bleeding disorders for the years 2024-2028\", which includes the delivery of the aforementioned medicinal products to regional blood donation and hemotherapy centers and/or other entities indicated by the national blood center in warsaw. 7. the ordering party reserves the right to cancel the proceedings or withdraw from the contract without compensation for the contractor with effect ex nunc, in the event that at least one of the following premises occurs: 7.1. the national blood center does not receive funding for the implementation of the health policy program entitled \"national program for the treatment of patients with hemophilia and related bleeding disorders for the years 2024-2028\" in the expected year of contract execution in whole or in part allowing for the execution of the contract. 7.2. the minister of health decides on the lack of modification of the program, modification of the program, withdrawal from execution or suspension of execution of the \"national program for the treatment of patients with hemophilia and related bleeding disorders for the years 2024-2028\" or makes changes to the content of the program resulting in the deletion of the medicinal product that is the subject of the order/contract. 8. based on article 256 of the pzp act, the ordering party may cancel the procurement procedure appropriately before the deadline for submitting offers if circumstances arise that make further conduct of the procedure unjustified. 9. according to article 257 of the pzp act, the ordering party may cancel the procurement procedure if the public funds that the ordering party intended to allocate to finance all or part of the order have not been granted to it. 10. the distributor of direct recipients for whom the subject purchase is made along with the ordered quantity of the subject of the order needed for purchase, in order to ensure the uninterrupted implementation of the health policy program of the minister of health entitled \"national program for the treatment of patients with hemophilia and related bleeding disorders for the years 2024-2028\", will be provided after signing the contract with the selected contractor by the national blood center within a timeframe agreed upon with the contractor, according to the reported current demand. 11. the order must be executed in accordance with the requirements specified in the swz and in the draft provisions of the agreement. lot-0002, title: part 2. concentrate of recombinant factor viii minimum ii generation along with delivery to regional blood donation and hemotherapy centers., description: 1. the subject of the order is the delivery of a concentrate of recombinant factor viii minimum ii generation to ensure the continuity of treatment for patients with hemophilia a - hereinafter referred to as \"coagulation factor\", with availability category rp or rpz, to the entities indicated by the national blood center (hereinafter nck) or another authorized entity of direct recipients - regional blood donation and hemotherapy centers (hereinafter rckik), under the terms specified in the content of the swz. 2. total quantity (purchase size): 5,000,000 iu. 3. dose proportions in each delivery - according to swz. 4. the coagulation factor concentrate must be delivered with a set enabling its administration. 5. when selecting the most advantageous offer, the ordering party reserves the right to reduce the purchase of the medicinal product, but not more than 20% of each part of the aforementioned subject of the order, in the event of exceeding the amount allocated for the execution of the order or the emergence of objective and justified needs, especially changes in demand among patients. 6. the purchase is carried out under the health policy program of the minister responsible for health entitled \"national program for the treatment of patients with hemophilia and related bleeding disorders for the years 2024-2028\", which includes the delivery of the aforementioned medicinal products to regional blood donation and hemotherapy centers and/or other entities indicated by the national blood center in warsaw. 7. the ordering party reserves the right to cancel the proceedings or withdraw from the contract without compensation for the contractor with effect ex nunc, in the event that at least one of the following premises occurs: 7.1. the national blood center does not receive funding for the implementation of the health policy program entitled \"national program for the treatment of patients with hemophilia and related bleeding disorders estimated value excluding vat: 1944444.44 pln.Concentrate of recombinant factor viii minimum second generation along with delivery to regional blood donation and transfusion centers; procedure sign: zzp.zp.411.158.2026 parts: 1÷2